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   Abstract.      Accuracy of an rK39 rapid diagnostic test (DiaMed-IT-Leish  ®  ) for visceral leishmaniasis (VL) was com-
pared with splenic aspiration and the direct agglutination test (DAT) in a population with a high prevalence of infection 
with human immunodeficiency virus (HIV) in Ethiopia. There were 699 patients clinically suspected of having VL (153 
parasitologically confirmed, 482 DAT confirmed, and 130 DAT negative), and 97 DAT-negative controls. A total of 84% 
were tested for HIV and 34% were HIV positive. Sensitivity of the rK39 test in parasitologically confirmed VL patients 
was 84% (77% in HIV positive and 87% in HIV negative;   P   = 0.25). Sensitivity of the DAT was higher (94%;   P   = 0.01), 
89% in HIV-positive patients and 95% in HIV-negative patients;   P   = 0.27). Specificity of the rK39 test was 99% in DAT-
negative controls and 92% in DAT-negative patients clinically suspected of having VL. A diagnostic algorithm combin-
ing DAT and the rK39 test had a sensitivity of 98% in HIV-positive VL patients and 99% in HIV-negative VL patients. 
Despite the lower sensitivity in a population with a high prevalence of HIV, the DiaMed-IT-Leish  ®   rK39 test enables 
decentralization of diagnosis. Patients clinically suspected of having VL who show negative results on the rK39 antigen 
test should undergo follow-up DAT testing, especially if they are HIV positive.     
     INTRODUCTION 
 Visceral Leishmaniasis (VL or Kala-azar) is a systemic para-
sitic disease transmitted by phlebotomine sand flies. The caus-
ative parasite in east Africa is   Leishmania donovani .  Visceral 
leishmaniasis is endemic in some regions in the southern and 
northwestern lowlands of Ethiopia. Since 1997, Médecins 
Sans Frontières (MSF) has established two VL treatment 
centers in the northwestern leishmaniasis-endemic region of 
Ethiopia, where 500–2,000 VL patients are treated annually. 
Because access to treatment is limited, incidence is probably 
much higher. The prevalence of human immunodeficiency 
virus (HIV) in the counseling and testing centers in the area is 
11–13% (MSF data) and 29% among VL patients.  1  
 Clinical diagnosis of VL is inaccurate. The experience of MSF 
in eastern Africa is extensive, with more than 80,000 VL cases 
treated since 1989. In our centers, only approximately 50% of 
patients fulfilling the clinical case definition for VL (history 
of fever for > 2 weeks with splenomegaly and/or lymphade-
nopathy) have confirmed VL; the rest have diseases includ-
ing malaria, typhoid, or disseminated tuberculosis. Accurate 
diagnosis is essential. Visceral leishmaniasis is generally fatal 
if untreated, and sodium stibogluconate, the most commonly 
used drug for treatment of patients with VL, has serious tox-
icity. Early diagnosis of VL requires an accurate test that is 
simple, rapid, does not require a laboratory or refrigeration, 
non-invasive, and suitable for use in remote settings. 
  Parasitologic diagnosis by direct microscopy of spleen aspi-
rates has a reported sensitivity of 96%,  2   but spleen aspirates 
are impractical and potentially unsafe in remote settings with 
large numbers of suspected cases. Lymph node aspiration is 
safe but among 8,000 patients suspected of having VL, we 
found a sensitivity of only 65%.  3   We have had disappointing 
experience with bone marrow aspirates (MSF, unpublished). 
  Serologic tests have been developed for diagnosis of VL. 
The direct agglutination test (DAT) is standard in most MSF 
VL treatment centers. Although specifically developed for 
field conditions, the DAT requires a sufficiently equipped lab-
oratory with skilled technicians, meticulous implementation, 
and overnight incubation. Samples need to be transported to 
a central laboratory if a peripheral one cannot be established, 
resulting in treatment delay of 1–2 weeks. 
 DAT  titers  ³ 1:3,200 have a high sensitivity and can be used 
to confirm a diagnosis of VL. Conversely, a low DAT titer 
(£ 1:400) effectively rules out VL.  4   If the patient has a DAT 
titer of > 1:400 but < 1:3,200, an aspiration is performed to 
confirm a diagnosis of VL. The MSF uses this diagnostic 
protocol, which reduces the number of aspirates by approxi-
mately 80%.  5  
 Lower and even negative titers for antibodies to  Leishmania  
spp. have been observed in the Mediterranean region in per-
sons with advanced HIV infection and VL.  6,7   In Ethiopia, the 
overall reported sensitivity of the DAT (56% of VL patients 
were HIV infected) was 97.7%. Among parasitologically con-
firmed VL cases, a false-negative DAT result was obtained 
in only 2 (3.9%) of the 51 cases that were HIV co-infected 
and in none of the 40 HIV-negative VL cases.  8   In a clinical 
study in Ethiopia, no difference was found in mean DAT titers 
between HIV-positive and HIV-negative VL patients.  1   Thus, 
the DAT appears to be reasonably sensitive in the diagnosis of 
VL in patients co-infected with HIV in Ethiopia. 
  Dipstick serologic tests have been developed by using the 
cloned antigen of the 39-amino acid repeats of a kinesin-like 
gene (rK39) found in   Leishmania chagasi .  The  DiaMed-IT-
Leish  ®   (DiaMed AG, Cressier-sur-Morat, Switzerland) was 
evaluated in VL patients in Sudan and showed a sensitivity of 
90%, a specificity of 99%, positive predictive value of 98%, and 
a negative predictive value of 71%.  9   In Uganda, it showed sen-
sitivity of 97% and a specificity of 99%.  10   In India, it showed a 
sensitivity of 99–100% and a specificity of 95–100%.  11  930 TER HORST AND OTHERS
  A meta-analysis of the diagnostic performance of the DAT 
and rK39 test, which did not include the above mentioned 
newer DiaMed-IT-Leish test results, showed sensitivities of 
94.8% for the DAT and 93.9% for rK39 in HIV-negative 
parasitologically confirmed VL cases.  12   Regional differ-
ences were noted; the tests are more sensitive in south Asia 
than in Sudan, which highlights the importance of validat-
ing new diagnostic tests in leishmaniasis-endemic areas. An 
Ethiopian study  13   showed a sensitivity of 95.3% for the DAT 
and 71.7% for rK39 (Kalazar Detect Rapid Test  ® ;  InBios 
International Imc., Seattle, WA) (active case detection for 
most cases, no HIV testing performed). Data on 38 passively 
recruited patients in Ethiopia clinically suspected of having 
VL in another study  14   showed a sensitivity of 94.0% and a 
specificity of 93.6% for the DAT and a sensitivity of 75.4% 
and a specificity of 70.0% for rK39 (Kalazar Detect Rapid 
Test  ® ;  InBios). 
  Few studies have assessed the role of HIV infection on the 
performance of the rK39 test, and high globulin titers found in 
patients infected with HIV might reduce specificity and lower 
titers of antibodies to   Leishmania   spp. might reduce the sensi-
tivity of the test. Because of the increasing geographic overlap 
of HIV and VL in east Africa, it is important to determine the 
accuracy of the rK39 test in HIV-positive VL patients. Thus, we 
compared the performance of the rK39 rapid test (DiaMed-
IT-Leish  ®  ) for the diagnosis of VL in the northwest region of 
Ethiopia with the DAT and splenic aspirate in HIV-positive 
and HIV-negative VL patients. 
   METHODS 
  Study site.   We conducted the study in the MSF VL treatment 
center at the Kahsay Abera Hospital in Humera in northwest-
ern Ethiopia from June 2006 through January 2007. 
      Patients and routine diagnostic algorithm.    Patients  without 
previous VL treatment who fulfilled the clinical VL case defi-
nition were eligible to join the study. All consenting patients 
were tested with the DAT, the rK39 test, and, where appropri-
ate, splenic aspiration. Aspirations were performed by an MSF 
physician. Contraindications to splenic aspiration were severe 
anemia (hemoglobin level < 6 g/dL), active bleeding, jaundice, 
advanced pregnancy, impalpable spleen, or inability to lie still 
during and after aspiration. 
  The DAT was performed on a blood spot from a fingerprick. 
A DAT titer ³ 1:3,200 in patients suspected of having VL was 
regarded as diagnostic, and a titer £ 1:400 as exclusion of VL. In 
patients with titers £ 1:400, other diagnoses were sought or the 
DAT was repeated in a week. Those patients with DAT titers 
between these values were considered indeterminate; these 
patients underwent spleen aspiration. Patients who appeared 
severely ill were additionally treated so that a diagnosis was 
made as quickly as possible. These patients underwent an 
aspiration on the same day as the DAT. If the initial aspirate 
result was negative, a repeat aspiration was performed the 
next day with or without a repeat DAT in those patients with 
negative results and clinically suspected of having VL. An 
experienced MSF laboratory technician performed all DAT 
examinations, aspirate slide readings, and rK39 tests during 
the study period (blinded for the patient’s previous results). 
Each dipstick was read by a different laboratory technician 
blinded to the results of the first technician to assess inter-
reader variability. 
  A parasitologically confirmed VL case was defined as a 
patient with a positive splenic aspiration smear. A negative 
control was defined as patients seen in Humera Hospital for 
reasons other than VL, with no signs and symptoms of VL, 
a negative DAT result, and no history of previous treatment 
for VL. 
   RK39  rapid  diagnostic  test.     The diagnostic test kit (rK39 
rapid test) was obtained from DiaMed AG, Switzerland. A fin-
gerprick sample of blood was used and the result is available in 
20 minutes. The procedures have been described elsewhere.  9  
   Direct  agglutination  test.     The DAT was performed by using 
whole dry blood spots on Whatman 3 filter paper (Whatman, 
Maidstone, United Kingdom) and freeze-dried antigen con-
taining   L. donovani   promastigotes (supplied by the Royal 
Tropical Institute, Amsterdam, The Netherlands). The qual-
ity of the DAT antigen was controlled by comparing it with a 
set of serum samples with known titers supplied by the Royal 
Tropical Institute. The DAT titer of the sample is the highest 
dilution at which agglutination is still visible. 
   Parasitologic  diagnosis.     Spleen aspirates were performed by 
the MSF physicians in charge of the patient. Giemsa-stained 
smears from splenic aspirates were examined by our labora-
tory technicians using oil-immersion microscopy. Parasite den-
sity was graded on a scale from 0 to 6+.  15  
   HIV  counseling  and  testing.     We offered HIV counseling 
and testing with informed consent to all adult VL patients. 
The HIV testing was performed by nurse counselors using 
two rapid tests (HIV-Determine; Abbott Diagnostics, Abbott 
Park, IL and Unigold; Trinity Biotech, Bray, Ireland) run in 
parallel. Results were confirmed with repeat testing in the lab-
oratory using the same tests on a second sample by a trained 
technician. The HIV status was not known for all study par-
ticipants. Those patients in whom VL was excluded were not 
routinely offered HIV testing. In addition, a few VL patients 
refused testing and some died before testing could be offered. 
The HIV-positive patients were referred to the free medical 
HIV/AIDS care center for ongoing care. 
   Tuberculosis and malaria co-infection.   We tested all patients 
suspected of having VL for malaria by blood film or rapid 
diagnostic test (Paracheck  ®  ; Orchid Biomedical Systems, Goa, 
India and/or Parascreen  ®  ; Zephyr Biomedical Systems, Goa, 
India). We recorded a history of tuberculosis at enrollment 
and assessed for tuberculosis if clinically indicated during 
hospitalization. 
   Statistical  analysis.     We entered data into an Excel  ®  
(Microsoft, Redmond, WA) spreadsheet. We performed sta-
tistical analysis using SPSS version 11 software (SPSS Inc., 
Chicago, IL) by chi-square test with Yates’ correction or 
Fisher’s exact test as appropriate. 
   Quality  control.     External quality control of splenic aspirates 
was performed sequentially by three independent laborato-
ries. The International Clinical Laboratories in Addis Ababa 
reviewed 26% of the positive slides and 32% of negative slides, 
and the Ethiopian Health and Nutrition Research Institute in 
Addis Ababa and our senior MSF laboratory technician re-
read a random sample of these results. External quality con-
trol of DAT was performed on dried blood spot filter papers 
of 20% of negative and intermediate DAT results. 
   Ethical  considerations.     All medical care was provided free 
of charge. We conducted the study in collaboration with the 
Regional Bureau of Health in Tigray, the Ethiopian Health 
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Abera Hospital in Humera. The only modification of rou-
tine care involved a fingerprick for the rK39 test. All eligible 
patients provided written informed consent. Visceral leish-
maniasis nurses explained the study to patients in the local 
language. Ethical approval was obtained from the Ethiopian 
Science and Technology Committee, the Tigray Regional 
Bureau of Health, the Humera Hospital director, and the MSF 
Ethics Review Board. 
    RESULTS 
  We enrolled 699 patients fulfilling the VL clinical case def-
inition without previous VL treatment. Of these, 491 (70%) 
had confirmed VL: 153 had a positive splenic aspirate, 482 had 
a DAT titer ³ 1:3,200, and 144 had both of these results. A total 
of 130 patients suspected of having VL had VL excluded by 
a DAT titer £ 1:400. The mean ± SD age of the total sample 
population was 25.4 ± 10.1 years. The male-to-female ratio was 
15:1 (reflecting the large male migrant worker population), 
the mean ± SD body mass index was 16.4 ± 2.5 kg/m  2  , and the 
mean ± SD spleen size was 9.1 ± 5.5 cm. 
  Among parasitologically confirmed VL cases, 128 (83.7%) 
of 153 underwent HIV testing and 44 (34.4%) of these 128 
patients were HIV positive. Among serologically confirmed 
VL cases, 224 (46.5%) of 482 underwent HIV testing, and 60 
(26.8%) of 224 were HIV positive. Co-infection with tuber-
culosis was confirmed in 21 VL patients (4.4%), 8 (38%) of 
whom were co-infected with HIV. Tuberculosis was clini-
cally suspected in an additional 28 patients (5.8%), 7 (25%) 
of whom were co-infected with HIV. Malaria co-infection was 
found in 26 VL patients (5.4%), 1 (3.8%) of whom was co-
infected with HIV. 
    Sensitivity of rK39 test and DAT in parasitologically con-
firmed VL patients.     The rK39 test result was positive in 129 
of 153 parasitologically confirmed VL patients (sensitivity = 
84.3%), with no significant difference between those patients 
who were HIV positive (34 of 44, 77.3%) and those patients 
who were HIV negative (73 of 84, 86.9%) (  P   =  0.25)  ( Table  1               ). 
  The DAT showed a diagnosis of VL (titer ³ 1:3,200) in 144 
of 153 parasitologically confirmed VL cases (sensitivity = 
94.1%), with no significant difference between those patients 
who were HIV positive (39 of 44, 88.6%) and those patients 
who were HIV negative (80 of 84, 95.2%) (  P   = 0.27). Overall 
sensitivity of the rK39 test was significantly lower than that of 
the DAT (odds ratio = 0.34, 95% confidence interval = 0.14–
0.79,   P   = 0.01). 
  Mean ± SD DAT titer and distribution in parasitologi-
cally confirmed HIV/VL co-infected patients (titer 8.8 ± 2.1) 
and HIV-negative VL patients (9.3 ± 1.9) was not signifi-
cantly different (  P   =  0.2)  ( Table  2               and   Figure  1  ).  However, 
parasite density was significantly higher in HIV/VL co-
infected patients than in HIV-negative patients (mean ± SD 
grade = 3.7 ± 1.7 versus 2.5 ± 1.3;   P   = 0.0001) (  Table 2   and 
  Figure 2    ). This 1.2 grade difference is equivalent to a nearly 
16-fold increased parasite density in aspirates from HIV 
co-infected patients. 
  The diagnosis of VL by either a positive rK39 test result or 
a positive DAT result yielded a high sensitivity in all parasite-
confirmed patients (98.7%), whether HIV negative (sensitiv-
ity = 98.8%) or HIV positive (sensitivity = 97.7%) (  Table 1  ). 
      Specificity of the rK39 test in DAT-negative patients and 
in DAT-negative controls.     The rK39 test result was negative 
in 119 of 130 patients clinically suspected of having VL who 
had DAT titers £ 1:400, giving a specificity of 91.5% for the 
DAT. Among 97 DAT-negative controls, 96 were rK39 nega-
tive  (specificity  =  99.0%)  ( Table  3             ).  Specificity  of  the  rK39  test 
in patients with intermediate DAT titers and negative splenic 
aspirates was 83% (25 of 30). 
      Comparison of the rK39 test to the combination of the DAT 
and splenic aspiration.     In Ethiopia, a diagnosis of VL is made 
if DAT titers are ³ 1:3200 or a splenic aspirate is positive for 
leishmanial parasites. Visceral leishmaniasis is excluded either 
by DAT titers £ 1:400 or DAT titers < 1:3,200 in combination with 
a negative aspirate result. Using this definition of VL, we deter-
mined that the rK39 test had a sensitivity of 64.6% (42 of 65) 
and a specificity of 66.7% (4 of 6) in patients co-infected with 
HIV. In HIV-negative patients, the sensitivity was 81.0% (136 
of 168) and the specificity was 81.8% (9 of 11). The positive pre-
dictive value of the rK39 test was 95.5% in patients co-infected 
with  HIV  and  98.6%  in  HIV-negative  patients  ( Table  4              ). 
      Proposed algorithm for rK39 test use for patients suspected 
of having VL in Ethiopia.     We assessed the performance of the 
rK39 test in a diagnostic algorithm (  Figure 3    ). If 200 patients 
clinically suspected of having VL come to a clinic, approxi-
mately 100 will have VL (assumed sensitivity of 50% of the 
clinical case definition). If immediately tested by using the rK39 
test, 84 will be correctly diagnosed (sensitivity = 84.3%) and 8 
will be incorrectly diagnosed (specificity = 91.5%). The remain-
ing 108 patients will be further investigated, of whom 16 will 
have a positive DAT result. Fifteen of these patients will be cor-
rectly diagnosed by a positive DAT result (sensitivity = 95%) 
and one will be incorrectly diagnosed (specificity = 95%). Two 
patients with indeterminate DAT titers will undergo splenic 
aspirate, with 1 of them being positive. A negative DAT result 
 T able  1 
  Sensitivity of the rK39 test and direct agglutination test in parasitologically confirmed patients with visceral leishmaniasis* 
Test
Overall, no. positive/no. tested, 
sensitivity  (95% CI)
HIV negative, no. positive/no. tested, 
sensitivity  (95% CI)
HIV positive, no. positive/no. tested, 
sensitivity  (95% CI) Odds ratio (95% CI)   P 
rK39 DiaMed-IT-Leish  ®   test 129/153, 84.3% (77.6–89.7%) 73/84, 86.9% (77.8–93.3%) 34/44, 77.3% (62.2–88.5%) 0.51 (0.18–1.46) 0.253
DAT (titer ³ 1:3,200) 144/153, 94.1% (89.1–97.3%) 80/84, 95.2% (88.3–98.7%) 39/44, 88.6% (75.4–96.2%) 0.39 (0.08–1.80) 0.273
rK39 test plus DAT 151/153, 98.7% (95.4–99.8%) 83/84, 98.8% (93.5–100%) 43/44, 97.7% (88.0–99.9%) 0.52 1.00
    *     CI = confidence interval; HIV = human immunodeficiency virus; DAT = direct agglutination test.   
 T able  2 
  DAT titer and parasite density and HIV status in 128 parasitologically 
confirmed patients with VL* 
Characteristic HIV positive HIV negative   P 
Sample SD 44 84
Mean ± DAT titer 8.8 ± 2.1 9.3 ± 1.9 0.216
Mean ± SD parasite grade 3.7 ± 1.7 2.5 ± 1.3 0.0001
    *      DAT = direct agglutination test; HIV = human immunodeficiency virus; VL = visceral 
leishmaniasis.  932 TER HORST AND OTHERS
in 98 patients will correctly eliminate VL in 97 patients and 
falsely eliminate VL in 1 patient (sensitivity = 99%). 
   Quality  control.     There was 100% agreement among two 
laboratory technicians who read the rK39 test dipsticks inde-
pendently and blinded for results. There was 97.5% agreement 
between splenic aspirate results of the Humera Laboratory 
and the aforementioned quality control laboratories. For DAT 
results, agreement was 96.3%. 
    DISCUSSION 
  We have demonstrated that HIV-positive VL patients in 
Ethiopia DAT titers similar to those of HIV-negative VL 
patients, a result that was previously reported,  1  which indicates 
preservation of antibody responses to   Leishmania   spp. pro-
mastigotes. Reassuringly, 88.6% of HIV co-infected patients 
can be diagnosed non-invasively by the DAT. The rK39 test 
diagnosed only 77.3% of HIV co-infected patients. This test 
has good specificity in controls (99.0%) and in DAT-negative 
patients suspected of having VL (91.5%). Our rK39 test speci-
ficity estimation is possibly slightly overestimating true spec-
ificity because there might have been DAT false-negative 
controls because of imperfect sensitivity of the DAT. The pre-
dictive value of a positive rK39 test result was high (> 95%) in 
clinically suspected cases irrespective of HIV status. 
  The sensitivity of the DiaMed-IT Leish  ®   rK39 test was 
lower than that reported in previous studies.  9,10   Some of 
this difference is related to the lower sensitivity in HIV 
co-infected patients. However, these patients did not have 
lower titers of antibodies to   Leishmania   spp., as indicated by 
DAT titer. Antibodies detected by the rK39 test, although 
present, may have had lower affinities, and thus less able to 
react in a rapid reaction (dipstick format) than in overnight 
incubation (as in the DAT test). The sensitivity we found in 
HIV-negative VL patients (87%) is similar to the sensitiv-
ity of 90% we reported in a study using the same dipstick in 
patients from southern Sudan who had a low prevalence of 
HIV.  9   When comparing studies, it is important to note which 
commercially available version of the rK39 test is being used. 
For example, we found poor performance in Sudan using a 
different prototype of the rK39 test.  16   There are also impor-
tant geographic differences that can affect this test. Chappuis 
and others,  10   Diro and others,  13   and Boelaert and others  14  
reported disappointing results in Africa with the Kalazar 
Detect Rapid Test  ®   (InBios). However, this test showed good 
performance in India. 
 In contrast to the observations made for patients co-infected 
with HIV and VL in Europe, the DAT in Ethiopia remains rea-
sonably sensitive in the diagnosis of VL in patients co-infected 
with HIV. The DAT titer distributions were similar in parasi-
tologically confirmed VL cases who were HIV positive and 
those who were HIV negative. The high sensitivity of the DAT 
we observed in patients co-infected with HIV and VL (89%) 
confirms previous findings in patients in Ethiopia co-infected 
with HIV and VL.  14  
  The nearly 16-fold higher parasite density found in splenic 
aspirates of patients co-infected with HIV implies that diag-
nosis by microscopy is sensitive in such patients. Thus, micros-
copy should remain the gold standard until non-invasive 
  Leishmania   antigen- or DNA-based tests are suitable for field 
use. We encountered no complications with this procedure. 
  An important finding is that, despite suboptimal sensi-
tivities of the rK39 test, the combination of both serologic 
tests in HIV-positive, parasitologically confirmed VL cases 
showed a high sensitivity (97.7%, 95% confidence interval = 
88.0–99.9%). This finding demonstrates that apparently a sig-
nificant part of the sensitivity of each separate test does not 
overlap. Therefore, use of the DAT after a negative rK39 result 
is obtained for a clinically suspected VL patient co-infected 
with HIV patient will improve VL detection, and the number 
of splenic aspirates can be greatly reduced. The ease of use of 
the rK39 dipstick test and its low cost enable early diagnosis 
of VL in decentralized settings and thereby improve access to 
early life-saving treatment. 
 F igure  1.        Direct agglutination test titer distribution and human 
immunodeficiency virus status in 128 parasitologically confirmed 
patients with visceral leishmaniasis.       
  F igure  2.  Distribution of parasite density and human immuno-
deficiency virus status in 128 parasitologically confirmed patients with 
visceral  leishmaniasis.    
 T able  3 
  Specificity of the rK39 test in DAT-negative patients clinically 
suspected of having VL and DAT-negative controls* 
Group Sample Specificity 95% CI
DAT-negative controls 97 96/97 99.0% 94.4–100%
DAT-negative patients clinically 
suspected of having VL 130 119/130 91.5% 85.4–95.7%
    *     DAT = direct agglutination test; VL = visceral leishmaniasis; CI = confidence interval.   933 RK39 AND DAT IN HIV CO-INFECTED VISCERAL LEISHMANIASIS
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 T able  4 
  Performance of rK39 test compared with the MSF diagnostic algorithm of DAT and aspirate (positive = DAT titer ³ 1:3,200 and/or aspirate posi-
tive; negative = DAT titer < 1:3,200 and aspirate negative)* 
Characteristic HIV negative HIV positive Odds ratio   P 
Sample 179 71
Sensitivity, % (95% CI) 81.0 (74.2–86.8) 64.6 (51.8–76.1) 0.43 (0.22–0.85) 0.014
Specificity, % (95% CI) 81.8 (48.2–97.7) 66.7 (22.3–95.7) 0.44 (0.03–6.96) 0.58
PPV, % (95% CI) 98.6 (94.9–99.8) 95.5 (84.5–99.4) 0.31 (0.03–3.18) 0.25
NPV, % (95% CI) 22.0 (10.6–37.6) 14.8 (4.2–33.7) 0.62 (0.14–2.59) 0.68
    *     MSF = Médecins Sans Frontières; DAT = direct agglutination test; HIV = human immunodeficiency virus; CI = confidence interval; PPV = positive predictive value; NPV = negative predic-
tive value.   
  F igure  3.  Flow chart of proposed algorithm for rK39 test using 200 patients suspected of having VL.       934 TER HORST AND OTHERS
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